Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China flag China · Delayed Price · Currency is CNY
54.20
-0.64 (-1.17%)
Nov 13, 2026, 3:00 PM CST

SHA:688621 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,0101,2201,077930.98676.39492.86
Other Revenue
1.91.91.611.140.210.79
1,0121,2221,078932.12676.61493.65
Revenue Growth
-0.57%13.33%15.70%37.76%37.06%42.12%
Cost of Revenue
497.61560.8537.33403.77301.15229.97
Gross Profit
514.13661.45541.14528.35375.46263.68
Selling, General & Admin
220.61193.64150.44153.24110.8185.63
Research & Development
176.28161.56171.94123.6889.6947.58
Other Operating Expenses
26.831.880.760.20.160.04
Operating Expenses
477.42452.22364.82334.89219.32143.72
Operating Income
36.71209.23176.32193.46156.14119.97
Interest Expense
-4.17-16.45-16.11-12.18-9.7-3.56
Interest & Investment Income
7.297.555.678.538.782.52
Other Non Operating Income (Expenses)
-71.13-2.95-2.66-2.47-0.96-0.72
EBT Excluding Unusual Items
-31.3197.37163.22187.35154.25118.21
Impairment of Goodwill
-5.55-5.55----
Gain (Loss) on Sale of Investments
---1.82---
Gain (Loss) on Sale of Assets
0.270.39-0.31-0.71-0.25-0.51
Asset Writedown
-23.79-----
Other Unusual Items
29.7516.5414.96.7615.144.4
Pretax Income
-30.62208.75175.99193.4169.14122.1
Income Tax Expense
-37.06-1.766.9710.510.4313.31
Earnings From Continuing Operations
6.44210.51169.01182.9158.7108.79
Minority Interest in Earnings
-0.4-6.658.41.86-2.23-3.13
Net Income
6.04203.87177.41184.76156.47105.66
Net Income to Common
6.04203.87177.41184.76156.47105.66
Net Income Growth
-95.46%14.91%-3.98%18.08%48.09%45.81%
Shares Outstanding (Basic)
11111011211211298
Shares Outstanding (Diluted)
11111011211211298
Shares Change
0.64%-2.38%0.28%0.19%14.09%16.84%
EPS (Basic)
0.051.861.581.651.401.08
EPS (Diluted)
0.051.861.581.651.401.08
EPS Growth
-95.49%17.72%-4.24%17.86%29.80%24.80%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-164.6450.781.5419.90.093.29
Free Cash Flow Per Share
-1.480.460.010.180.000.03
Dividend Per Share
0.1870.1870.1630.1650.4290.189
Dividend Growth
14.72%14.72%-1.21%-61.50%126.41%-
Gross Margin
50.82%54.12%50.18%56.68%55.49%53.41%
Operating Margin
3.63%17.12%16.35%20.76%23.08%24.30%
Profit Margin
0.60%16.68%16.45%19.82%23.13%21.40%
Free Cash Flow Margin
-16.27%4.15%0.14%2.14%0.01%0.67%
EBITDA
61.73235.12203.39216.9173.19131.47
EBITDA Margin
6.10%19.24%18.86%23.27%25.60%26.63%
D&A For EBITDA
25.0225.927.0723.4417.0511.5
EBIT
36.71209.23176.32193.46156.14119.97
EBIT Margin
3.63%17.12%16.35%20.76%23.08%24.30%
Effective Tax Rate
--3.96%5.43%6.17%10.90%
Revenue as Reported
366.491,2221,078932.12676.61493.65
Advertising Expenses
-1.270.581.691.171.13